PATENT CLAIM ANALYSIS

Application Number: 15753045
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "252160"]

Abstract:
The present disclosure relates to pharmaceutical combinations comprising (a) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, and (b) an epidermal growth factor receptor (EGFR) inhibitor, for the treatment or prevention of cancer. The disclosure also provides related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.

Claim (Index 10):
The pharmaceutical combination of  claim 1 , for use in the manufacture of a medicament for the treatment or prevention of cancer.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 88.0
- Lexical Diversity: 1.53659
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15755140', '14414998', '15755122', '13799706', '15882620']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7918379773067529
- 35 USC 102 Novelty (BERT): 0.52955273869418
- Combined Prediction Score: 0.7656094534454956
- Mean Citation Score: 284.788728
- Max Citation Score: 340.7501200000001
- Similarity Product: 221.4273904870296

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test